FDA’s NDA backlog reduced
Executive Summary
As of the end of June, four NDAs are overdue by more than one year and 37 NDAs are overdue by less than one year. At the same time last year, 75 NDAs were overdue. The number of efficacy supplements pending decreased to 61, the lowest level since 1990.